Crizotinib Package Insert

NEW DRUG UPDATE 2017 - Ncop.memberlodge.org
NEW DRUG UPDATE 2017 Jolynn K. Sessions, Pharm.D., BCOP August 5, 2017 . progression on crizotinib March 27 Zejula Niraparib Ovarian, peritoneal, fallopian cancers Lartruvo package insert. Eli Lilly and Company. 2016 . Olaratumab - dosing ... Access Doc

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Crizotinib is extensively metabolized in the liver. Treatment with crizotinib should be used with caution in patients with hepatic impairment (see Table 2 and sections 4.4, 4.8 and 5.2). Based on the National Cancer Institute (NCI) classification, no starting dose adjustment of crizotinib is ... Retrieve Doc

Non-Small Cell Lung Cancer - Mayo Clinic
Non-Small Cell Lung Cancer Survival Rates. 2016 Stage 5-year survival rate IA 49% IB 45% IIA 30% • 65% with crizotinib vs. 20% with chemotherapy • CNS disease and resistance [package insert]. Genentech USA, Inc., South San Francisco, CA. 2016 ... Document Viewer

CASE REPORT Crizotinib-induced Pancreatic Pseudocyst: A Novel ...
Crizotinib is a tyrosine kinase inhibitor that inhibits anaplastic lymphoma kinases (ALKs).1 Crizotinib can potentially lead to a dramatic tumour response in patients with advanced non-small cell lung cancers harbouring ALK rearrangements.23The package insert for crizotinib approved by the US Food and Drug Administration states that ... Read Document

Evaluation Of Adherence To Monitoring Parameters For Oral ...
Evaluation of adherence to monitoring parameters for Crizotinib Monthly Every 2 weeks for first 2 months Imatinib Weekly for first month, biweekly for second month Zytiga® [package insert].Horsham, PA: Janssen Biotech; 2016 4. ... Visit Document

Xalkori® (crizotinib) - Specialty Pharmacy Home Page
XALKORI® (crizotinib) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2018, Magellan Rx Management 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Crizotinib. National Comprehensive Cancer Network, 2018. The NCCN ... Fetch This Document

ABOUT LORLATINIB ALK In NSCLC ROS1 In NSCLC PRECLINICAL DATA ...
Zou H., Li, Q. et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proceedings of the National Academy of Sciences. ... Read Document

HIGHLIGHTS OF PRESCRIBING INFORMATION With A Fluoropyrimidine ...
KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. 1.2 Non-Small Cell Lung Cancer KEYTRUDA, in combination with pemetrexed andplatinum chemotherapy, isindicated for thefirst-line treatment of patients with metastatic nonsquamousnon-small cell lung cancer (NSCLC), with no EGFR or ... Return Doc

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: HEMORRHAGE,GASTROINTESTINAL PERFORATION, AND IMPAIRED WOUND HEALING 1 INDICATIONS AND USAGE 1.1 Gastric Cancer 1.2 Non-Small Cell Lung Cancer 1.3 Colorectal Cancer 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dose and Schedule 2.2 Premedication 2.3 Dose Modifications 2.4 Preparation for Administration ... Fetch Content

Development Of Crizotinib For The Treatment Of ALK-positive ...
DRUG: Crizotinib - Indications and Usage 1 XALKORI ® is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ... Doc Viewer

Jakafi Prescribing Information
Jakafi is a kinase inhibitor indicated for treatment of patients with: • intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. ... Read Document

XALKORI (crizotinib) - Caremark
XALKORI (crizotinib) RATIONALE FOR INCLUSION IN PA PROGRAM . Background . Xalkori is a kinase inhibitor indicated for the treatment of patients with metastatic nonsmall cell - Xalkori [package insert]. New York, NY: Pfizer Inc.; February 2018. ... Access Full Source

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Ovarian Cancer GEMZAR®in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ... Retrieve Full Source

PATIENT INFORMATION A HALAVEN (HAL-ih-ven) HALAVEN (eribulin ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HALAVEN safely and effectively. See full prescribing information for HALAVEN. ... Get Doc

The Renal Effects Of ALK Inhibitors - Link.springer.com
1 are used, namely crizotinib, ceritinib and alectinib. Several more agents are in active pre-clinical and clinical studies. Crizotinib is approved for the treatment of ad-vanced ALK-positive non-small cell lung cancer (NSCLC). According to the package insert and published literature, treatment with crizotinib appears to be associ- ... Access Doc

Cobimetinib - Wikipedia
Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech . It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. ... Read Article

Advanced Non-small Cell Lung Cancer With TKI And PD-1 Drugs
Documentation results of genetic testing where required per drug package insert. Documentation results of all required laboratory values and patient-specific information (e.g., weight, ALT/AST, and creatinine kinase) when recommended or required per drug package (Zykadia), or crizotinib ... Doc Retrieval

Lestaurtinib - Wikipedia
Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. ... Read Article